Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
ELCC 2017
The 7th European Lung Cancer Conference
Access to all presentations that took place at ELCC 2017 in Geneva, Switzerland
Presentation Date(s):- May 5 – 8, 2017
- Total Presentations: 359
-
+
Opening and welcome
- Type: Opening and welcome
- Presentations: 1
- Moderators:M. Reck
- Coordinates: 5/05/2017, 13:30 - 13:45, Room B
-
+
Welcome to ELCC
13:30 - 13:45
- Abstract
No abstract available for this presentation
-
+
Immunotherapy of non-small cell lung cancer
- Type: Educational session
- Presentations: 5
- Moderators:S. Peters
- Coordinates: 5/05/2017, 16:30 - 18:00, Room B
-
+
First-line treatment
16:30 - 16:50 | Author(s): M. Reck
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
Keynote lecture: Genetic profiling of lung cancer
- Type: Keynote Lecture
- Presentations: 1
- Moderators:M. Reck
- Coordinates: 5/06/2017, 14:10 - 14:40, Room B
-
+
Genetic profiling of lung cancer
14:10 - 14:40 | Author(s): M. Meyerson
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
The role of antiangiogenic agents in NSCLC: Are we making progress?
- Type: Young Oncologist session
- Presentations: 3
- Moderators:M. Reck
- Coordinates: 5/07/2017, 08:00 - 08:50, Room X
-
+
State of the art in first and subsequent lines of the NSCLC treatment
08:00 - 08:20 | Author(s): B. Besse
- Abstract
No abstract available for this presentation
-
+
Biomarker approaches for optimisation of antiangiogenic therapy
08:20 - 08:40 | Author(s): M. Reck
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Discussion
08:40 - 08:50
- Abstract
No abstract available for this presentation
-
+
Is there a role for second-line immunotherapy in patients with PD-L1 negative NSCLC?
- Type: Controversy session
- Presentations: 4
- Moderators:M. Reck
- Coordinates: 5/07/2017, 09:15 - 10:15, Room A
-
+
Introduction and first vote
09:15 - 09:25 | Author(s): M. Reck
- Abstract
No abstract available for this presentation
-
+
Yes
09:25 - 09:45 | Author(s): R. Herbst
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
No
09:45 - 10:05 | Author(s): B. Besse
- Abstract
No abstract available for this presentation
-
+
Second vote and conclusions
10:05 - 10:15 | Author(s): L. Paz-Ares
- Abstract
No abstract available for this presentation
-
+
Poster Display Session
- Type: Poster Display Session
- Presentations: 142
- Coordinates: 5/07/2017, 12:30 - 13:00, Hall 1
-
+
58TiP - IMpower133: Phase I/III trial of first-line atezolizumab with carboplatin and etoposide in ES-SCLC
12:30 - 12:30 | Author(s): M. Reck
- Abstract
Loading... -
+
119P - A phase 2 randomized open-label study of ramucirumab (RAM) plus first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): Final results from squamous pts
12:30 - 12:30 | Author(s): S. Thomas
- Abstract
Loading... -
+
120P - Subgroup analysis of adenocarcinoma patients refractory to first-line chemotherapy from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non–small cell lung cancer (NSCLC)
12:30 - 12:30 | Author(s): M. Reck
- Abstract
Loading... -
+
139TiP - A non-interventional biomarker study in patients (pts) with non-small cell lung cancer (NSCLC) of adenocarcinoma histology who are treated with nintedanib according to the approved label (LUME-BioNIS)
12:30 - 12:30 | Author(s): M. Reck
- Abstract
Loading... -
+
144TiP - CheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Author(s): L. Paz-Ares
- Abstract
Loading... -
+
146TiP - EXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Author(s): L. Horn
- Abstract
Loading...
-
+
ESMO-IASLC Best Abstracts
- Type: Best abstracts session
- Presentations: 6
- Moderators:A.G. Nicholson
- Coordinates: 5/07/2017, 16:45 - 18:15, Room B
-
+
81O - Safety and efficacy analyses of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients with or without baseline brain metastases
16:45 - 17:00 | Author(s): R.V. Lukas
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
82O - Durvalumab in ≥ 3rd-line EGFR mutant/ALK+, locally advanced or metastatic NSCLC: Results from the phase 2 ATLANTIC study
17:00 - 17:15 | Author(s): M. Garassino
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Invited Discussant 81O and 82O
17:15 - 17:30 | Author(s): S. Peters
- Abstract
No abstract available for this presentation
-
+
LBA1 - Establishment of a diagnostic algorithm for ROS1 testing in Canada
17:30 - 17:45 | Author(s): M.S. Tsao
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
147O - Correlation of molecular status and anatomic sites of metastases (mets) at diagnosis (Dx) of non-small cell lung cancer (NSCLC)
17:45 - 18:00 | Author(s): C. Kuijpers
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Invited Discussant LBA1 and 147O
18:00 - 18:15 | Author(s): A.G. Nicholson
- Abstract
No abstract available for this presentation
-
+
Closing remarks
- Type: Closing remarks
- Presentations: 1
- Moderators:M. Reck
- Coordinates: 5/08/2017, 12:50 - 13:00, Room A
-
+
Closing remarks
12:50 - 13:00 | Author(s): A.G. Nicholson
- Abstract
No abstract available for this presentation
